There are no risk factors associated with the development of pulmonary hamartomas, nor are there defined screening guidelines, considering the mostly sporadic nature of the lesions. Considering the risk, albeit small, of malignant change and development of subsequent malignancy, patients should be advised to adhere to a schedule conservative observation in the form of periodical imaging and comparison with previous results.